^
    Back
    Association details:
    Biomarker:VEGFA elevation
    Cancer:Hepatocellular Cancer
    Drug:Lenvima (lenvatinib) (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    Clin Cancer Res
    Title:

    Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase 3 REFLECT Study

    Published date:
    06/09/2021
    Excerpt:
    407 patients were included in the serum analysis set (lenvatinib n=279, sorafenib n=128); 58 patients were included in the gene-expression analysis set (lenvatinib n=34, sorafenib n=24)….Higher baseline VEGF, ANG2, and FGF21 correlated with shorter OS in both treatment groups.
    DOI:
    10.1158/1078-0432.CCR-20-4219
    Trial ID:
    REFLECT